Status:
COMPLETED
Inhaled Prostacyclin for Adult Respiratory Distress Syndrome (ARDS) and Pulmonary Hypertension
Lead Sponsor:
Aga Khan University
Collaborating Sponsors:
Medical Research Council, Pakistan
Conditions:
Adult Respiratory Distress Syndrome
Pulmonary Hypertension
Eligibility:
All Genders
16+ years
Phase:
NA
Brief Summary
Summary of the proposed research: The intravenous application of prostacyclin (PGE1) or its stable analogue, iloprost, has been used to cause a decrease not only of the pulmonary but also of the syst...
Detailed Description
Introduction: Pulmonary hypertension, defined as mean PA (pulmonary arterial) pressure of \> 25 mm Hg, is an end point of a variety of conditions. These include primary pulmonary hypertension, post-o...
Eligibility Criteria
Inclusion
- After obtaining informed consent the following patients will be included:
- All patients admitted to the ICU with pulmonary hypertension (mean PA \> 35 mmHg).
- All patients in ICU with post operative pulmonary HTN (mean PA \> 35 mm Hg).
- All patients with ARDS (PaO2/FiO2 \< 200 - arterial hypoxemia, bilateral infiltrates on Chest X-ray infiltrates on CXR and a wedge \< 20 mm Hg on swan ganz parameters) or signs of heart failure.
Exclusion
- Patients to be excluded will be those with:
- Pulmonary embolus.
- Cor pulmonale.
- Ejection fraction of \< 30%, wedge \> 20 mm Hg.
- Non-intubated patients.
- Pediatric patients (\< 16 yrs of age).
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00314548
Start Date
May 1 2006
End Date
July 1 2009
Last Update
May 19 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.